Insulet first launched its Omnipod 5 patch-pump for people with Type 1 diabetes in 2022. Now, the device is also indicated for people with Type 2 diabetes ages 18 years and older. 

There are roughly 6 million people with Type 2 diabetes in the U.S. who take insulin, and roughly 2.5 million people in that group take multiple daily injections of insulin, the company said. 

In clinical trial results shared in June, Insulet said it tested its AID system in people with Type 2 diabetes who take multiple daily shots of insulin, as well as people who only take basal, or daily, insulin.

The company said it observed significant improvements in participants’ hemoglobin A1C levels, “regardless of prior therapy at the start of the trial.”